VolitionRx Joins French Government-Funded DETECSEPS Program for Early Sepsis Detection
VolitionRx Limited (NYSE AMERICAN: VNRX) has joined the DETECSEPS Consortium, a €6.3 million ($7.3 million)-funded initiative by the French government aimed at improving early detection of sepsis in emergency departments. The project is led by IHU SEPSIS and involves partners including AP-HP, HCL, IDS France (part of Revvity), and VolitionRx. Volition will supply its Nu.Q® NETs assay as the sole biomarker for evaluating patients at risk of sepsis upon arrival. The test measures levels of histone variant H3.1 using an automated analyzer provided by IDS France, with results available within one hour. Experts believe this could enhance triage accuracy and reduce unnecessary hospital admissions. Sepsis is a life-threatening condition affecting millions globally each year, making early detection critical for reducing mortality rates. The DETECSEPS program aims to integrate clinical scores with biomarker data in real-world settings across France.
Tickers: $RVTY
Topics: biomarker epigenetics government_funding sepsis